Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P8IV
|
|||
| Former ID |
DAP000536
|
|||
| Drug Name |
Dactinomycin
|
|||
| Synonyms |
Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Approved | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C62H86N12O16
|
|||
| Canonical SMILES |
CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C
|
|||
| InChI |
1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
|
|||
| InChIKey |
RJURFGZVJUQBHK-IIXSONLDSA-N
|
|||
| CAS Number |
CAS 50-76-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8990, 520465, 565029, 841047, 3141480, 5343980, 7847281, 8136899, 8151387, 11120223, 11120711, 11121199, 11147306, 11434891, 26752119, 29221206, 47216557, 47515096, 47588774, 47959487, 48034857, 48034858, 49854365, 50114308, 51071907, 57321102, 57392818, 74382088, 75117937, 85083371, 85789491, 95152991, 103185659, 103934097, 104299382, 124766124, 124886988, 125537037, 125767589, 126687205, 131332481, 134337828, 137156344, 137545216, 160964308, 161005131, 162022425, 162022855, 164787451, 174007348
|
|||
| ChEBI ID |
CHEBI:27666
|
|||
| ADReCS Drug ID | BADD_D00571 | |||
| SuperDrug ATC ID |
L01DA01
|
|||
| SuperDrug CAS ID |
cas=000050760
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Target Info | Breaker | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050682. | |||
| REF 2 | Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.